Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Sells 5,214 Shares of Stock

by · The Cerbat Gem

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) EVP Yakob Liawatidewi sold 5,214 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $271,388.70. Following the sale, the executive vice president now owns 74,938 shares of the company’s stock, valued at approximately $3,900,522.90. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Amphastar Pharmaceuticals Stock Up 4.8 %

AMPH stock traded up $2.22 during midday trading on Friday, reaching $48.31. 626,882 shares of the company’s stock traded hands, compared to its average volume of 397,490. The company has a quick ratio of 2.63, a current ratio of 3.52 and a debt-to-equity ratio of 0.82. The firm’s fifty day moving average price is $48.45 and its 200-day moving average price is $44.13. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92. The company has a market cap of $2.35 billion, a price-to-earnings ratio of 15.43, a P/E/G ratio of 0.97 and a beta of 0.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.10. The company had revenue of $182.39 million for the quarter, compared to analyst estimates of $171.29 million. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. As a group, sell-side analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.67 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on AMPH shares. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Finally, Piper Sandler reduced their price target on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, Amphastar Pharmaceuticals has a consensus rating of “Hold” and an average target price of $63.00.

Read Our Latest Research Report on Amphastar Pharmaceuticals

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Mutual of America Capital Management LLC grew its holdings in Amphastar Pharmaceuticals by 11.3% during the first quarter. Mutual of America Capital Management LLC now owns 97,683 shares of the company’s stock worth $4,289,000 after buying an additional 9,926 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S raised its holdings in shares of Amphastar Pharmaceuticals by 62.9% in the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 12,455 shares of the company’s stock valued at $547,000 after purchasing an additional 4,811 shares during the last quarter. Texas Permanent School Fund Corp lifted its position in shares of Amphastar Pharmaceuticals by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 32,704 shares of the company’s stock valued at $1,436,000 after purchasing an additional 424 shares in the last quarter. Quantbot Technologies LP purchased a new position in Amphastar Pharmaceuticals during the first quarter worth about $481,000. Finally, Concurrent Investment Advisors LLC bought a new stake in Amphastar Pharmaceuticals in the 1st quarter worth about $693,000. Institutional investors own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

(Get Free Report)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

See Also